Avacta Group Yönetim
Yönetim kriter kontrolleri 1/4
Avacta Group's CEO is Chris Coughlin, appointed in May 2024, has a tenure of less than a year. directly owns 0.014% of the company’s shares, worth £27.01K. The average tenure of the management team and the board of directors is 1.7 years and 0.4 years respectively.
Anahtar bilgiler
Chris Coughlin
İcra Kurulu Başkanı
UK£53.0k
Toplam tazminat
CEO maaş yüzdesi | n/a |
CEO görev süresi | less than a year |
CEO sahipliği | 0.01% |
Yönetim ortalama görev süresi | 1.7yrs |
Yönetim Kurulu ortalama görev süresi | less than a year |
Son yönetim güncellemeleri
Recent updates
Is Avacta Group (LON:AVCT) Using Debt Sensibly?
Oct 29Avacta Group Plc's (LON:AVCT) 29% Share Price Surge Not Quite Adding Up
Sep 05Improved Revenues Required Before Avacta Group Plc (LON:AVCT) Shares Find Their Feet
Jun 21Investors Give Avacta Group Plc (LON:AVCT) Shares A 26% Hiding
Feb 23Getting In Cheap On Avacta Group Plc (LON:AVCT) Is Unlikely
Aug 05Would Avacta Group (LON:AVCT) Be Better Off With Less Debt?
Jun 22We're Hopeful That Avacta Group (LON:AVCT) Will Use Its Cash Wisely
Oct 20This Is The Reason Why We Think Avacta Group Plc's (LON:AVCT) CEO Deserves A Bump Up To Their Compensation
Jun 22Avacta Group (LON:AVCT) Is In A Good Position To Deliver On Growth Plans
Jun 20Avacta Group Plc (LON:AVCT) Insiders Have Been Selling
Feb 18Companies Like Avacta Group (LON:AVCT) Are In A Position To Invest In Growth
Jan 23CEO
Chris Coughlin (54 yo)
less than a year
Görev süresi
UK£53,000
Tazminat
Dr. Christina M. Coughlin, also known as Chris, BS, MD, PH D., was Head of Research and Development of Avacta Group Plc from February 1, 2024 and serves as its Chief Executive Officer from May 01, 2024 and...
Liderlik Ekibi
İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
---|---|---|---|---|
CEO, Interim Chief Medical Officer and Director | less than a year | UK£53.00k | 0.014% £ 27.0k | |
CFO & Company Secretary | 8.8yrs | UK£409.00k | 0.0022% £ 4.4k | |
Group In-House Counsel | no data | Veri yok | Veri yok | |
Group Communications Director | 3.8yrs | Veri yok | Veri yok | |
Chief Operating Officer of Diagnostics | 8.3yrs | UK£69.00k | Veri yok | |
Chief Commercial Officer of Diagnostics | 1.8yrs | Veri yok | Veri yok | |
Chief Operating Officer of Therapeutics Division | 1.7yrs | Veri yok | Veri yok | |
Joint Managing Director of Launch Diagnostics | 1.6yrs | Veri yok | Veri yok | |
Joint Managing Director of Launch Diagnostics | 1.6yrs | Veri yok | Veri yok | |
Chief Business Officer of Therapeutics | less than a year | Veri yok | Veri yok | |
Chief Operating Officer of Coris BioConcept | 1.7yrs | Veri yok | Veri yok | |
Managing Director of Launch Diagnostics Deutschland GmbH | less than a year | Veri yok | Veri yok |
1.7yrs
Ortalama Görev Süresi
54yo
Ortalama Yaş
Deneyimli Yönetim: AVCT's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
Yönetim Kurulu Üyeleri
İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
---|---|---|---|---|
CEO, Interim Chief Medical Officer and Director | 2.7yrs | UK£53.00k | 0.014% £ 27.0k | |
Independent Non-Executive Director | 11.3yrs | UK£47.00k | 0.029% £ 58.0k | |
Non Executive Director | less than a year | Veri yok | Veri yok | |
Non-Executive Independent Chairman | 1.4yrs | UK£26.00k | 0.011% £ 21.6k | |
Independent Non-Executive Director | 3.3yrs | UK£53.00k | Veri yok | |
Independent Non-Executive Director | 4.8yrs | UK£47.00k | Veri yok | |
Member of Scientific Advisory Board | less than a year | Veri yok | Veri yok | |
Chairman of Scientific Advisory Board | less than a year | Veri yok | Veri yok | |
Member of Scientific Advisory Board | less than a year | Veri yok | Veri yok | |
Member of Scientific Advisory Board | less than a year | Veri yok | Veri yok | |
Member of Scientific Advisory Board | less than a year | Veri yok | Veri yok | |
Member of Scientific Advisory Board | less than a year | Veri yok | Veri yok |
0.4yrs
Ortalama Görev Süresi
62.5yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: AVCT's board of directors are not considered experienced ( 0.4 years average tenure), which suggests a new board.